Skip to content
Open access

Cardiovascular–kidney–metabolic risk stratification and cardiorenal outcomes with SGLT2 inhibitors versus GLP-1 receptor agonists in type 2 diabetes: a global federated network study

Oct 2026 · European Heart Journal · Vol 47 · 0 citations

TL;DR

A consistent cardiorenal benefit pattern was observed across low, moderate and high CKM strata, with SGLT2i reducing renal outcomes and GLP-1RA conferring greater cardiovascular protection.

Abstract

Obesity is common among patients with type 2 diabetes (T2D) and cardiovascular–kidney–metabolic (CKM) comorbidities, yet the comparative effectiveness of SGLT2 inhibitors (SGLT2i) versus GLP-1 receptor agonists (GLP-1RA) remains uncertain. We compared obese versus non-obese risk profiles and evaluated SGLT2i versus GLP-1RA for major adverse cardiovascular events (MACE) and major adverse kidney events (MAKE), stratified by obesity status and CKM comorbidity burden. We conducted a retrospective cohort study using TriNetX including adults with T2D between 2013 and 2024. Patients were classified by CKM comorbidity burden: low CKM risk (CKM0–1, one or none of hypertension, chronic kidney disease, or hyperlipemia); moderate CKM risk (CKM2, two comorbidities); high CKM risk (CKM3, all three comorbidities, metabolically extremely unhealthy). Within each CKM risk group, patients were further stratified by obesity status (BMI ≥30 kg/m²). Primary outcomes were MACE and MAKE. Secondary outcomes included heart failure (HF), atrial fibrillation (AF), and all-cause mortality. Propensity score matching (PSM) and Cox regression were applied. After PSM, obese patients in the high CKM risk group had higher risks of HF (HR 1.35, 95% CI 1.33–1.37), AF (HR 1.33, 95% CI 1.31–1.35), MACE (HR 1.03, 95% CI 1.01–1.04), and MAKE (HR 1.06, 95% CI 1.04–1.08) compared with non-obese patients [Figure1]. Within the high CKM risk group, SGLT2i were associated with lower MAKE compared with GLP-1RA in both obese (HR 0.55, 95% CI 0.50–0.61) and non-obese patients (HR 0.48, 95% CI 0.41–0.56). In contrast, SGLT2i were associated with higher risks of MACE compared with GLP-1RA in obese (HR 1.34, 95% CI 1.25–1.44) and non-obese patients (HR 1.18, 95% CI 1.07–1.30). A consistent cardiorenal benefit pattern was observed across low, moderate and high CKM strata, with SGLT2i reducing renal outcomes and GLP-1RA conferring greater cardiovascular protection. Compared with SGLT2i, GLP-1RA were associated with lower all-cause mortality among obese patients with low and moderate CKM risk (low CKM risk: HR 1.27, 95% CI 1.19–1.36; moderate CKM risk: HR 1.13, 95% CI 1.06–1.21) [Figure2]. Obesity in patients with high CKM risk was associated with increased risks of MACE, MAKE, HF, and AF. SGLT2i were associated with lower risks of MAKE, whereas GLP-1RA were associated with lower risks of MACE, HF, and AF. Among obese patients with low or moderate CKM risk, GLP-1RA were associated with lower all-cause mortality.Obese vs non-obese cardiorenal outcomesSGLT2i vs GLP-1RA across obesity strata

Read PDF

Similar papers

Nov 2026

Abstract 14486: Comparative Cardiovascular and Mortality Outcomes of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Propensity Score-Matched Cohort Study

GLP-1 RA therapy was associated with significantly lower risks of major adverse cardiovascular outcomes and all-cause mortality compared with SGLT2 inhibitors, suggesting a potential advantage of GLP-1 RA therapy for long-term cardiovascular risk reduction in patients with T2DM.

Sajjad Ahmed Khan, Anurag Marasini · 0 citations
Nov 2026

Abstract 16799: Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Patients with Prior Myocardial Infarction and Overweight or Obesity: A Propensity-Matched Analysis

In patients with prior MI and overweight or obesity, GLP-1 RA use was associated with substantially lower risk of MACE and new-onset heart failure than SGLT2i, with consistent benefit across ischemic and pulmonary vascular outcomes and neutral effects on mortality.

Zaid Al-Kofahi, H. Alhammouri, F. Qtaishat et al. · 0 citations
Nov 2026

Abstract 11617: Cardiovascular Outcomes in Patients with Fatty Change of Liver Treated with Combined GLP-1 RA and SGLT2 Inhibitor Therapy versus GLP-1 RA Alone: A Propensity Score Matched TriNetX Analysis

Background: Fatty change of the liver is strongly associated with cardiovascular risk due to insulin resistance, dyslipidemia, and systemic inflammation. GLP-1 receptor agonists (GLP-1 RAs) and SGLT2 inhibitors (SGLT2is) each provide independent cardiovascular benefits. This study assesses whether combination therap...

M. Azhar, Aneesa Altaf, Ehsanullah Alokozay et al. · 0 citations
Nov 2026

Abstract 14909: GLP-1 Receptor Agonist Add-On Therapy versus Continued SGLT2 Inhibitor Monotherapy and Kidney Failure in Adults with Type 2 Diabetes and CKD Stages 3-4: A Propensity-Matched Real-World Analysis

Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce kidney and cardiovascular risk in chronic kidney disease (CKD), yet residual risk remains substantial. Whether the addition of glucagon-like peptide-1 receptor agonists (GLP-1RA) provides incremental renal and cardiovascular benefit among patients...

Sylvia Osei-Akuamoah, Kwame Adjei-Sefah, Y. Kebede et al. · 0 citations
Nov 2026

Abstract 15618: Incremental Cardiovascular Benefit of GLP-1 Therapy in Patients with HFrEF and Type 2 Diabetes on Quadruple GDMT

Background: Patients with heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus (T2DM) remain at high residual cardiovascular risk despite guideline-directed medical therapy (GDMT). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated cardiometabolic benefits, but their...

Sultana Jahan, Ali Awad, M. Al-Mollah et al. · 0 citations
Nov 2026

Abstract 14627: GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Limb and Mortality Outcomes in Patients with Peripheral Artery Disease and Type 2 Diabetes

Background: Patients with peripheral artery disease (PAD) and type 2 diabetes mellitus (T2DM) are at high risk of major adverse limb events (MALE), amputation, and mortality. Although GLP1 receptor agonists (GLP1-RAs) and SGLT2 inhibitors improve cardiovascular outcomes, their comparative and combined associations w...

M. Alnees, Nizar Abu Hamdeh, Y. Fraitekh et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.